{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/leg-ulcer-venous/prescribing-information/co-amoxiclav/","result":{"pageContext":{"chapter":{"id":"a6cda703-9039-5115-b3d3-478cdb4d1e55","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav","depth":2,"htmlHeader":"<!-- begin field cf4bec72-c52f-4093-9400-aa9000b70987 --><h2>Co-amoxiclav</h2><!-- end field cf4bec72-c52f-4093-9400-aa9000b70987 -->","summary":"","htmlStringContent":"<!-- begin item 9f83b045-b2fd-4075-bce7-aa9000b7093e --><!-- end item 9f83b045-b2fd-4075-bce7-aa9000b7093e -->","topic":{"id":"627b2b3c-014b-5543-8f89-0f3ffa6344ad","topicId":"4c5db985-9544-48b2-8c54-8915ec210739","topicName":"Leg ulcer - venous","slug":"leg-ulcer-venous","lastRevised":"Last revised in January 2021","chapters":[{"id":"01818c5e-efb9-59c4-b339-08b834294232","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"313e84c5-8bc7-5150-826a-467ea7252acd","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"2597db24-8ec5-54d4-86ad-8082be50f4f6","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"38f24092-0019-582d-86bf-d1f61bccde1d","slug":"changes","fullItemName":"Changes"},{"id":"cdc15e74-0503-53a5-a4be-c53ec4e20898","slug":"update","fullItemName":"Update"}]},{"id":"73d0cf59-f9c0-5785-8c74-e756826d5d1e","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"64b11689-d52a-560f-8d9b-c592d654615e","slug":"goals","fullItemName":"Goals"},{"id":"ac3d1637-467f-5edb-8fd8-73f66160080f","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"4bffe5b2-0ce0-5ae8-8c0b-914bb6ed5a1d","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"82441da5-60f5-53b4-b510-187f7bacb4a8","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"3e5817d5-30e7-54b7-b9ba-224b4a295bba","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"b30bb006-efbc-5a69-90f3-30abf232a97d","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"84dc0da0-8533-5c5d-99f6-7c04a116701a","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"45d8d35d-9757-544c-b04e-9747898a1f0e","slug":"definition","fullItemName":"Definition"},{"id":"21acb832-e5e8-5bd1-9b8d-9410ec5011bf","slug":"causes-risk-factors","fullItemName":"Causes and risk factors"},{"id":"cf27bd7b-b787-5def-bb40-ee0f134a8aca","slug":"prevalence","fullItemName":"Prevalence"},{"id":"a55a1739-f3d2-534c-b533-f6406d9c81ea","slug":"complications","fullItemName":"Complications"},{"id":"683b612a-3f1d-5580-951b-e14672f52b4a","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"dbc94220-a914-56d0-883d-d158da511e1c","fullItemName":"Diagnosis","slug":"diagnosis","subChapters":[{"id":"57b3b7a5-9042-53fa-a236-56d0d02b647e","slug":"assessment","fullItemName":"Assessment"},{"id":"35ee8784-602e-5a29-9ccf-65b3c3f940d2","slug":"interpretation-of-abpi","fullItemName":"Interpretation of ABPI"},{"id":"0c766f2c-0c8f-521b-85fd-e947ba6b2d09","slug":"differential-diagnosis","fullItemName":"Differential diagnosis"}]},{"id":"5e199f8a-7621-5318-9da1-264db8f544b8","fullItemName":"Management","slug":"management","subChapters":[{"id":"c8bda10b-ebb6-533b-9c91-96efa5ddf0c3","slug":"venous-leg-ulcers","fullItemName":"Scenario: Venous leg ulcers"}]},{"id":"e084faba-a409-53ac-aa53-08b80a3991f1","fullItemName":"Prescribing information","slug":"prescribing-information","subChapters":[{"id":"66a7f656-c6f5-57a2-a08a-1533a6fd4e92","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"a6cda703-9039-5115-b3d3-478cdb4d1e55","slug":"co-amoxiclav","fullItemName":"Co-amoxiclav"},{"id":"1cf75cbb-8bc4-58cc-9a1b-11516db5ad2c","slug":"co-trimoxazole","fullItemName":"Co-trimoxazole"},{"id":"3f0efc32-779b-56f6-85ca-e46a59745bed","slug":"doxycycline","fullItemName":"Doxycycline"},{"id":"fe306aab-d8d7-5181-a461-128f2aa3c65a","slug":"erythromycin","fullItemName":"Erythromycin"},{"id":"314a80d5-e16b-5625-8d64-4141535ff392","slug":"flucloxacillin","fullItemName":"Flucloxacillin"},{"id":"b7e7b8ec-799c-5ea5-9ac0-11935f899b8a","slug":"oral-analgesia","fullItemName":"Oral analgesia"},{"id":"43ed3b03-6322-5690-8f85-b6e10a0b3d3e","slug":"pentoxifylline","fullItemName":"Pentoxifylline"}]},{"id":"19f3ffbe-f365-5196-8586-0dceeaf69908","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"89207239-b8a4-50ce-8b2d-3065a830c0af","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"45831e7c-0e6f-50f3-a513-fe4fcacff65e","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"3d90cdb0-b2fd-5bfd-bd2d-342e36901f9d","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"8b66d1a4-6ee5-5556-b671-204219a81787","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"5b8ee442-8da6-524f-bf34-e6a9cc2a771e","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"6fa96be3-beae-51f6-9f1c-4d278b058d09","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"e75dc366-237b-55d2-a654-2e3bf503b955","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"e084faba-a409-53ac-aa53-08b80a3991f1","slug":"prescribing-information","fullItemName":"Prescribing information"},"subChapters":[{"id":"14a4011b-5d35-54df-9710-593637a5ebfd","slug":"contraindications-cautions","fullItemName":"Contraindications and cautions","depth":3,"htmlHeader":"<!-- begin field 1c7a12dd-2b26-4a4c-8638-aa9000b78f3c --><h3>What are the contraindications and cautions for co-amoxiclav?</h3><!-- end field 1c7a12dd-2b26-4a4c-8638-aa9000b78f3c -->","summary":"","htmlStringContent":"<!-- begin item 3d71afe2-6283-42ed-9f71-aa9000b78f22 --><!-- begin field c4754f5f-c463-4dd2-b801-aa9000b78f3c --><ul><li><strong>Do not prescribe </strong><strong>co-amoxiclav </strong><strong>to people with:</strong><ul><li>A <em>true </em>penicillin hypersensitivity.<ul><li><strong>Note that</strong> gastrointestinal adverse effects alone (such as nausea, vomiting, or diarrhoea) do <em>not </em>constitute an allergy to penicillin. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angio-oedema-anaphylaxis/\">Angio-oedema and anaphylaxis</a> for more information.</li></ul></li><li>A history of severe immediate hypersensitivity reaction to cephalosporins — there is some evidence of partial cross-allergenicity. </li><li>A history of co-amoxiclav- or penicillin-associated jaundice or hepatic dysfunction.</li></ul></li><li><strong>Prescribe co-amoxiclav with caution </strong><strong>to people with:</strong><ul><li>Hepatic impairment — monitor closely.</li><li>Chronic kidney disease (CKD) — reduce the <a class=\"topic-reference internal-reference\" href=\"/topics/leg-ulcer-venous/management/venous-leg-ulcers/#managing-infection\">dose</a> of co-amoxiclav based on the estimated glomerular filtration rate (eGFR):<ul><li>If the eGFR is 10–30 mL/minute/1.73 m<sup>2</sup>, prescribe one 500/125 strength tablet every 12 hours.</li><li>If the eGFR is less than 10 mL/minute/1.73 m<sup>2</sup>, prescribe one 500/125 strength tablet every 24 hours.</li></ul></li><li>Acute lymphocytic leukaemia, chronic lymphocytic leukaemia, cytomegalovirus infection, or glandular fever — increased risk of erythematous rashes.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">ABPI, 2018c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field c4754f5f-c463-4dd2-b801-aa9000b78f3c --><!-- end item 3d71afe2-6283-42ed-9f71-aa9000b78f22 -->","subChapters":[]},{"id":"7b13d377-9f0c-5c30-9769-91ce02f570dd","slug":"adverse-effects","fullItemName":"Adverse effects","depth":3,"htmlHeader":"<!-- begin field 503aa828-0aa6-407f-bf7e-aa9000b802af --><h3>What are the possible adverse effects of co-amoxiclav?</h3><!-- end field 503aa828-0aa6-407f-bf7e-aa9000b802af -->","summary":"","htmlStringContent":"<!-- begin item 67982c5f-fcb2-4efd-921b-aa9000b80295 --><!-- begin field 832ed012-8428-4945-b973-aa9000b802af --><ul><li><strong>Common and very common adverse effects of co-amoxiclav include </strong>nausea, vomiting, increased risk of infections (for example fungal infection and vaginitis), and diarrhoea [<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">ABPI, 2018c</a>]. <ul><li>Consider pseudomembranous colitis (an acute, exudative colitis caused by <em>Clostridium difficile</em>) if a person develops severe diarrhoea during or after treatment with co-amoxiclav. For more information, see the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/diarrhoea-antibiotic-associated/\">Diarrhoea - antibiotic associated</a>.</li></ul></li><li><strong>Anaphylaxis (delayed or immediate) </strong>is a serious but rare adverse effect of co-amoxiclav. See the CKS topic on <a class=\"topic-reference external-reference\" href=\"/topics/angio-oedema-anaphylaxis/\">Angio-oedema and anaphylaxis</a> for more information.</li><li><strong>Cholestatic jaundice</strong> can occur either during or shortly after the use of co-amoxiclav.<ul><li>It is more common in people over the age of 65 years and in men; these reactions have only rarely been reported in children. Jaundice is usually self limiting and very rarely fatal. The duration of treatment should be appropriate to the indication and should not usually exceed 14 days.</li></ul></li><li><strong>Other adverse effects of co-amoxiclav include:</strong><ul><li>Uncommon — dizziness, dyspepsia, headache, pruritus, skin rash, and urticaria.</li><li>Rare — reversible leucopenia (including neutropenia), thrombocytopenia, and erythema multiforme.</li><li>Frequency unknown — akathisia, aseptic meningitis, black hairy tongue, convulsion, crystalluria, haemorrhagic colitis, haemolytic anaemia, hypersensitivity vasculitis, reversible agranulocytosis, and severe cutaneous adverse reactions (SCARs).</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">ABPI, 2018c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 832ed012-8428-4945-b973-aa9000b802af --><!-- end item 67982c5f-fcb2-4efd-921b-aa9000b80295 -->","subChapters":[]},{"id":"33192116-9d59-5512-9ac7-757c143e37ae","slug":"drug-interactions","fullItemName":"Drug interactions","depth":3,"htmlHeader":"<!-- begin field d899009c-776a-4793-9f54-aa9000b88518 --><h3>What are the possible drug interactions with co-amoxiclav?</h3><!-- end field d899009c-776a-4793-9f54-aa9000b88518 -->","summary":"","htmlStringContent":"<!-- begin item 81a04abe-8aa5-4058-a86d-aa9000b88503 --><!-- begin field 84f86630-dc7e-4b24-87c8-aa9000b88518 --><ul><li><strong>Possible drug interactions with co-amoxiclav include:</strong><ul><li>Allopurinol — concurrent use of allopurinol and co-amoxiclav may increase the incidence of skin rashes.<ul><li>Manufacturer advises to consider alternatives.</li></ul></li><li>Methotrexate — amoxicillin is predicted to increase the risk of toxicity when given with methotrexate.<ul><li>If concurrent treatment is indicated, monitor methotrexate levels more closely. One recommendation is to carry out twice weekly platelet and white cell counts for 2 weeks initially, with the measurement of methotrexate levels if toxicity is suspected.</li></ul></li><li>Probenecid — the renal tubular secretion of amoxicillin is decreased by probenecid. Concurrent use may result in increased and prolonged blood levels of amoxicillin, but not of clavulanic acid.<ul><li>Manufacturer recommends avoiding concurrent use.</li></ul></li><li>Warfarin — penicillins potentially alter the anticoagulant effect of warfarin.<ul><li>Monitor the prothrombin time or international normalized ratio (INR) more closely with the addition or withdrawal of a penicillin. Adjustment of the warfarin dose may be necessary. </li></ul></li></ul></li><li><strong>Oral hormonal contraception</strong> — additional contraceptive precautions are not required during or after courses of penicillins [<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">FSRH, 2017</a>].<ul><li>However, advise women on the importance of correct contraceptive practice if they experience vomiting or diarrhoea. For further information, see the section on vomiting or diarrhoea in the CKS topics on <a class=\"topic-reference external-reference\" href=\"/topics/contraception-combined-hormonal-methods/\">Contraception - combined hormonal methods</a> and <a class=\"topic-reference external-reference\" href=\"/topics/contraception-progestogen-only-methods/\">Contraception - progestogen-only methods</a>.</li></ul></li></ul><p>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">ABPI, 2018c</a>; <a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">Joint Formulary Committee, 2019</a>]</p><!-- end field 84f86630-dc7e-4b24-87c8-aa9000b88518 --><!-- end item 81a04abe-8aa5-4058-a86d-aa9000b88503 -->","subChapters":[]},{"id":"e3760910-25fb-5ee5-b631-149e8ec13ca1","slug":"use-in-pregnancy-breastfeeding","fullItemName":"Use in pregnancy and breastfeeding","depth":3,"htmlHeader":"<!-- begin field 6b29dcaa-a277-48f2-9c6e-aaa300d8b1ed --><h3>Can co-amoxiclav be used during pregnancy and breastfeeding?</h3><!-- end field 6b29dcaa-a277-48f2-9c6e-aaa300d8b1ed -->","summary":"","htmlStringContent":"<!-- begin item 787254a9-8fa9-4849-91f1-aaa300d8b1cd --><!-- begin field 4767f4a7-fd8b-4250-b25a-aaa300d8b1ed --><ul><li><strong>Pregnancy</strong><ul><li>Co-amoxiclav is not known to be harmful in pregnancy [<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">Joint Formulary Committee, 2019</a>].</li><li>The vast majority of the large amount of available data shows no increased risk of congenital malformation, spontaneous abortion, intrauterine death, low birth weight, preterm delivery, or neonatal complications following maternal exposure to therapeutic doses of penicillins [<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">UKTIS, 2017b</a>].</li></ul></li><li><strong>Breastfeeding</strong><ul><li>Trace amounts of co-amoxiclav are found in breastmilk, but it is appropriate to use in women who are breastfeeding [<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">Joint Formulary Committee, 2019</a>].</li><li>Penicillins (and cephalosporins) are the antibiotics of choice in breastfeeding women [<a class=\"bibliography-reference internal-reference\" href=\"/topics/leg-ulcer-venous/references/\">Kearney, 2016</a>].</li></ul></li></ul><!-- end field 4767f4a7-fd8b-4250-b25a-aaa300d8b1ed --><!-- end item 787254a9-8fa9-4849-91f1-aaa300d8b1cd -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}